Celldex Therapeutics, Inc. (NASDAQ:CLDX) reported data from its ongoing Phase 1 study of the fully human monoclonal antibody varlilumab (CDX-1127) in cancer. Varlilumab is an immunotherapy designed to enhance the body’s natural immune response by directly activating T cells that can specifically recognize and kill cancer cells. Preclinical data support the broad study of varlilumab in combination with a number of other anti-cancer agents including but not limited to checkpoint inhibitors, chemotherapies, targeted therapies and vaccines. Varlilumab will enter at least four combination studies in the second half of 2014. Celldex Therapeutics, Inc. (NASDAQ:CLDX) weekly performance is 2.93%. On last trading day company shares ended up $13.69. Analysts mean target price for the company is $35.50. Celldex Therapeutics, Inc. (NASDAQ:CLDX) distance from 50-day simple moving average (SMA50) is -10.01%.
Roth Capital cut shares of ReneSola Ltd. (ADR) (NYSE:SOL) from a buy rating to a neutral rating in a research report sent to investors on Friday morning, TheFlyOnTheWall.com reports. ReneSola Ltd. (ADR) (NYSE:SOL) shares fell -6.30% in last trading session and ended the day on $2.38. Gross Margin is 6.80% and its return on assets is -11.40%. ReneSola Ltd. (ADR) (NYSE:SOL) quarterly performance is -35.33%.
On May 30, Vringo, Inc. (NASDAQ:VRNG), a company engaged in the innovation, development and monetization of intellectual property and mobile technologies, announced that the Patent Re-Examination Board of the State Intellectual Property Office of the People’s Republic of China has upheld the validity of Chinese Patent ZL00806049.5, owned by Vringo’s wholly-owned subsidiary Vringo Infrastructure, Inc. The patent, which is the Chinese equivalent of European Patent 1,166,589, was placed into re-examination by ZTE Corporation on November 6, 2012. Vringo, Inc. (NASDAQ:VRNG) shares moved down -5.47% in last trading session and was closed at $3.11, while trading in range of $3.10 – $3.27. Vringo, Inc. (NASDAQ:VRNG) year to date (YTD) performance is 5.07%.
Zogenix, Inc. (NASDAQ:ZGNX) a pharmaceutical company developing and commercializing products for the treatment of pain-related conditions and central nervous system disorders, reported that it has issued inducement awards to four new non-executive employees. Zogenix, Inc. (NASDAQ:ZGNX) ended the last trading day at $2.08. Company weekly volatility is calculated as 9.41% and price to cash ratio as 5.72. Zogenix, Inc. (NASDAQ:ZGNX) showed a positive weekly performance of 1.46%.
Medient Studios Inc (OTCMKTS:MDNT) the company which is engaged in developing content for US and India for entertainment purposes has finally focused on developing its lead property – Studioplex. The microcap company has not had a good run thus far and is expected to mark a good turn around with this development. Currently, the operations include the digging of a well, which is expected to complete operations in 280 days. Currently, 155 foot water tower is expected to hold 500,000 gallons of water. With the commencement of the new well, which has the potential to draw 2 million gallons per day, only 150,000 gallons are being drawn. Medient Studios Inc (OTCMKTS:MDNT) on last trading day company shares ended up $0.0034.